Study to understand the effectiveness and safety of Injection Sepsivac in the patients of Gram negative sepsis

Study of Inj. SepsivacÂ® in gram negative sepsis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2020/12/029825

Enrollment

Registered

2020-12-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A415- Sepsis due to other Gram-negativeorganisms

Interventions

Intervention1: Intravenous Mw and Standard of care treatment: single daily dose of 0.9 ml of Mw intravenous for 3 consecutive days and standard treatment of sepsis due to gram negative organisms Cont

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed to have sepsis due to gram negative organisms (clinical diagnosis)

Exclusion criteria

Exclusion criteria: Pregnant patients, patients of sepsis with other organism than gram negative, patient 65 years, patients not willing to provide consent

Design outcomes

Primary

Measure	Time frame
all-cause mortality Timepoint: 28 days	—

Secondary

Measure	Time frame
Days on ventilator and vasopressor, Intensive Care Unit length of stay, Change in SOFA score, To monitor adverse eventsTimepoint: 3, 7, 14, 28 days	—

Countries

India

Contacts

Public ContactDr Maharshi Desai

Apollo Hospitals

maharshi_desai@yahoo.com9825044828

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026